Episode15:Insilico Medicine, The 1st AIDD Company Delivered

End-to-End AI and Robotics Platform: Insilico has developed a commercially available, end-to-end platform that integrates generative AI and robotics to enhance the quality and productivity of pharmaceutical research. This platform includes:PandaOmics: A tool for aging research, disease modeling, and novel target discovery and prioritization.Generative Chemistry and Generative Biologics: Engines for designing and optimizing novel biomolecules, including on-the-fly optimization, kinase selectivity analysis, and relative binding free energy prediction.Alchemistry and ADMET Profiling: Platforms for predicting chemical properties, synthesis routes, and assessing the absorption, distribution, metabolism, excretion, and toxicity of drug candidates.Golden Cubes: A robotic lab for generating novel molecules.InClinico: A tool for designing and predicting clinical trials.PreciousGPT: A generative conversational agent that acts as a copilot for researchers.Strong Pipeline and Rapid Drug Development: Insilico Medicine boasts an extensive pipeline of over 30 internal research and development programs. They have successfully nominated nine preclinical candidates within one year and can advance from target discovery to initiating Phase I trials in under 30 months, significantly faster than the traditional 4.5 years.Successful Collaborations and Licensing Agreements: Insilico has secured notable collaboration and licensing agreements, demonstrating the value of their AI-driven approach. These include:A co-development agreement with Fosun Pharma.An out-licensing agreement with Exelixis.An out-licensing agreement with Menarini. etc.,

There are no comments yet.

Please log in to write the first comment.